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Abstract
Background: Platinum compounds such as cisplatin and carboplatin are DNA crosslinking agents widely used for
cancer chemotherapy. However, the effectiveness of platinum compounds is often tempered by the acquisition of
cellular drug resistance. Until now, no pharmacological approach has successfully overcome cisplatin resistance in
cancer treatment. Since the Fanconi anemia (FA) pathway is a DNA damage response pathway required for cellular
resistance to DNA interstrand crosslinking agents, identification of small molecules that inhibit the FA pathway may
reveal classes of chemicals that sensitize cancer cells to cisplatin.
Results: Through a cell-based screening assay of over 16,000 chemicals, we identified 26 small molecules that
inhibit ionizing radiation and cisplatin-induced FANCD2 foci formation, a marker of FA pathway activity, in multiple
human cell lines. Most of these small molecules also compromised ionizing radiation-induced RAD51 foci formation
and homologous recombination repair, indicating that they are not selective toward the regulation of FANCD2.
These compounds include known inhibitors of the proteasome, cathepsin B, lysosome, CHK1, HSP90, CDK and PKC,
and several uncharacterized chemicals including a novel proteasome inhibitor (Chembridge compound 5929407).
Isobologram analyses demonstrated that half of the identified molecules sensitized ovarian cancer cells to cisplatin.
Among them, 9 demonstrated increased efficiency toward FA pathway-proficient, cisplatin-resistant ovarian cancer
cells. Six small molecules, including bortezomib (proteasome inhibitor), CA-074-Me (cathepsin B inhibitor) and
17-AAG (HSP90 inhibitor), synergized with cisplatin specifically in FA-proficient ovarian cancer cells (2008+FANCF),
but not in FA-deficient isogenic cells (2008). In addition, geldanamycin (HSP90 inhibitor) and two CHK1 inhibitors
(UCN-01 and SB218078) exhibited a significantly stronger synergism with cisplatin in FA-proficient cells when
compared to FA-deficient cells, suggesting a contribution of their FA pathway inhibitory activity to cisplatin
sensitization.
Conclusion: Our findings suggest that, despite their lack of specificity, pharmaceutical inhibition of the FA pathway
by bortezomib, CA-074-Me, CHK1 inhibitors or HSP90 inhibitors may be a promising strategy to sensitize cisplatin-
resistant, FA pathway-proficient tumor cells to cisplatin. In addition, we identified four new small molecules which
synergize with cisplatin. Further development of their analogs and evaluation of their combination with cisplatin
may lead to the development of efficient cancer treatments.
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Platinum compounds, such as cisplatin (cis-diamminedi-
chloroplatinum(II)) and carboplatin, are DNA interstrand
crosslink (ICL)-inducing agents. ICLs bind both strands of
the DNA helix, inhibit DNA replication and RNA tran-
scription, and induce cell cycle arrest and apoptosis [1].
Platinum compounds are widely used for the treatment of
multiple cancers, including ovarian, testicular, lung and
some pediatric tumors [2]. Ovarian cancers initially
respond very well to platinum-based therapy. However,
many patients with ovarian cancer eventually relapse with
platinum-resistant disease.
Various platinum resistance mechanisms have been
proposed [2], including restoration of DNA repair [3].
Therefore, combination therapy using small molecules
that inhibit DNA repair pathways responsible for cellular
resistance to ICLs, such as Fanconi anemia (FA) pathway
inhibitors, is a logical strategy to overcome and prevent
platinum resistance.
FA is a rare genetic disease characterized by chromo-
somal instability, cancer susceptibility, aplastic anemia and
cellular hypersensitivity to ICLs [4,5]. The 15 FA proteins
[6,7] cooperate in the FA pathway, which coordinates mul-
tiple DNA repair mechanisms including endonuclease-
mediated DNA processing, translesion DNA synthesis and
homologous recombination (HR) [4,5]. Monoubiquitination
and nuclear foci formation of FANCD2 and FANCI are
crucial steps in the activation of this pathway [4,5,8].
The USP1/UAF1 deubiquitinase complex deubiquitinates
FANCD2 and reverses the FA pathway activation [9].
Mutation and silencing of genes controlling the FA pathway
have been linked to the development of tumors [10], and
are associated with increased ICL sensitivity. Restoration
of an intact FA pathway leads to the emergence of ICL-
resistant tumors [10–12]. Thus, small molecules that
inhibit the FA pathway may function as platinum chemo-
sensitizers and have clinical utility in restoring platinum
sensitivity of tumor cells.
We have developed a cell-based screening assay for
small molecules that inhibit the FA pathway, and pub-
lished partial results focusing on one of the hits, curcumin
[13]. Monoketone analogs of curcumin were subsequently
shown to have potent FA pathway inhibitory effects [14].
A cell-free screening assay using Xenopus egg extract also
identified 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone
as an FA pathway inhibitor [15]. Recently, the Nedd8
activated enzyme (NAE) inhibitor MLN4924 was shown
to sensitize cells to DNA damaging agents through
indirect inhibition of the Fanconi anemia pathway [16].
However, despite important efforts, no specific inhibitor of
the FA pathway has been identified so far.
In the current study, using a human cell-based assay, we
completed screening of more than 16,000 chemicals for
molecules that inhibit the FA pathway, and identified
26 small molecules that inhibit ionizing radiation (IR)-
induced FANCD2 foci formation. We further character-
ized these compounds for their ability to inhibit RAD51
foci assembly, HR, or proteasome activity, and we
compared their ability to sensitize ovarian cancer cells to
cisplatin. We show that about half of these chemicals
sensitized ovarian cancer cells to cisplatin, with in most
cases a significantly stronger synergism in FA-proficient
cells than in FA-deficient cells, suggesting that their effects
are, at least partially, mediated through inhibition of the
FA pathway.
Results
Cell-based screening for small molecules that inhibit the
FA pathway
Assembly of DNA damage-induced FANCD2 foci is a
widely used indicator of upstream FA pathway integrity
[8]. To identify novel small molecules that inhibit the FA
pathway, PD20-EGFP-FANCD2 cells [13] were treated
with chemical libraries and exposed to IR (15 Gy) to
induce FANCD2 foci formation. A significant decrease in
the proportion of cells with IR-induced EGFP-FANCD2
foci upon drug treatment was scored as positive
(Figure 1A). Using this cell-based assay, we tested more
than 16,000 chemicals, and identified 43 compounds
(0.27%) that significantly reduced EGFP-FANCD2 foci
formation in the initial screen (Additional file 1: Table S1),
including curcumin, wortmannin, alsterpaullone and H-9,
as previously described [13]. Fifteen of these 43 com-
pounds were then confirmed to inhibit IR-induced
FANCD2 foci formation in multiple cell lines, including
PD20-FANCD2, U2OS, HeLa and TOV21G+FANCF
ovarian cancer cells, using a wide range of drug concentra-
tions (Table 1, Figures 1B and 1C, Additional file 2: Figure
S1, and data not shown). Interestingly, some of the drugs
independently identified through this screen shared
common inhibitory features (Table 1): curcumin [17] and
compound 5929407 (see below) are proteasome inhibitors,
and curcumin, H-9, and Gö6976 are PKC inhibitors.
Eleven additional compounds, related to the chemicals
identified in our primary screen or identified in unrelated
studies [18], were also subjected to secondary screening:
two CHK1/PKC inhibitors (UCN-01, SB218078), a CDK
inhibitor (roscovitine), an HSP90 inhibitor (17-AAG), four
proteasome inhibitors (bortezomib, MG132, ALLN,
lactacystin), two compounds structurally related to
5656325 (5315179 and 7012246 (Additional file 2: Figure
S1)), and chloroquine. All of these compounds inhibited
DNA damage-induced FANCD2 foci assembly in multiple
cell lines, without altering the overall expression of EGFP-
FANCD2 or endogenous FANCD2 (Figure 1B, Additional
file 3: Figure S5 and data not shown). The dose required
to inhibit 50% of IR-induced EGFP-FANCD2 foci forma-
tion (IC50) in PD20-EGFP-FANCD2 cells was determined
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of them exhibited IC50 values lower than 10 μM. Although
the FA pathway inhibition capacity of these inhibitors may
not be due to specific targeting of components of the FA
pathway, we will refer to them as FA pathway inhibitors in
the remaining text for simplicity.
Identification of a novel proteasome inhibitor among the
small molecules that inhibit the FA pathway
All proteasome inhibitors tested (bortezomib, MG132,
ALLN, lactacystin, curcumin) inhibited FANCD2 foci for-
mation in multiple cell lines (Table 1 and [18]). Therefore,
we hypothesized that some of the newly identified FA
pathway inhibitors could also inhibit the proteasome. We
first tested proteasome activity using GFPu-1 cells, in
which inhibition of proteasome results in increased GFP
expression [19]. All proteasome inhibitors as well as
the Chembridge compound 5929407 induced a strong
increase in GFP expression in GFPu-1 cells (Figure 2A).
We then assessed the effects of these compounds on the
three proteases activities associated with the proteasome
(trypsin-like, chymotrypsin-like and caspase-like activities),
using fluorogenic compounds in HeLa cells extracts. All
compounds that increased GFP expression in GFPu-1
cells (bortezomib, MG132, lactacystin, ALLN, curcumin
and 5929407) inhibited chymotrypsin- and caspase-like
activities of the proteasome, the chymotrypsin-like activity
being generally the most affected. In addition, lactacystin
and curcumin inhibited trypsin-like activity (Figure 2B).
These findings indicate that the compound 5929407 is a
novel proteasome inhibitor that preferentially inhibits the
chymotrypsin-like activity of the proteasome.
Most chemicals that inhibit the FA pathway inhibit
homologous recombination
Since the FA pathway is required for efficient DNA
double-strand break repair by HR [4,20], we tested
whether the identified compounds affect HR efficiency in
human cells using the DR-GFP reporter system [21]. In
this assay, GFP expression reflects the occurrence of an
HR repair event; compounds that disrupt HR repair
will decrease GFP expression. Twenty-four hours after
transfection of a HA-tagged I-Sce1-encoding plasmid,
U2OS-DR-GFP cells were exposed to the identified FA
pathway inhibitors for 24 hours (Additional file 4A and B:
Figures S2A and B). The concentration used for each drug
was optimized to induce minimal decrease in cell viability
(more than 90% viable cells after 24 hours, Additional file
4C: figure S2C), and did not significantly affect HA-tagged
I-Sce1 expression (averaged 36.3% of the population for all
drugs in multiple experiments compared to 39.2% in the
non-treated population), with the exception of MG132,
UCN-01, compounds 5195423 and 7012246 (Additional
file 4D: Figure S2D). The HA-positive population was
analyzed for GFP expression. In the absence of drug,
9.5±0.9% of the HA-positive cells expressed GFP.
With the exception of SB218078, HNMPA-(AM)3 and
TPEN, all FA pathway inhibitors significantly decreased
HR (p ≤0.05) (Figure 3 and Additional file 4E and F:
Figures S2E and S2F). No significant differences in the cell
Figure 1 Chemical library screening for small molecules that inhibit the Fanconi anemia pathway. (A) Schematic of the screening for small
molecules that inhibit IR-induced FANCD2 foci formation. (B) Representative photomicrographs of EGFP-FANCD2 foci in PD20F-EGFP-FANCD2
cells untreated and treated with the indicated compounds at the indicated concentration. The cells were treated with compounds immediately
before irradiation (15 Gy), and fixed after 12 hours. (C) FANCD2 foci in HeLa cells untreated and treated with the indicated compounds at the
indicated concentration. The cells were fixed 8 hours after irradiation (10 Gy) and immunostained with anti-FANCD2 antibody. Scale bar=20 μm.
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except for UCN-01, 17-AAG, wortmannin, HNMPA-
(AM)3 and compounds 5929407 and 5315179 (Additional
file 5A: Figure S3A).
BRCA1 and RAD51 are required for efficient HR and
are known to interact with FANCD2 [8,22–24]. We
therefore tested whether the FA pathway inhibitors block
FANCD2, BRCA1 and RAD51 foci formation upon DNA
damage in U2OS-DR-GFP cells. To do so, we used drug
treatments identical to those used during the DR-GFP
assay, consisting in longer exposure (24 hours) to lower
concentrations of chemicals than the initial screen and
confirmation experiments. Under such conditions, most of
the drugs still significantly inhibited IR-induced foci
formation of FANCD2 and RAD51 (Figure 3 and
Additional file 6: Figure S4), without significantly modify-
ing cell cycle distribution (Additional file 5B: Figure S3B).
The drugs that failed to significantly inhibit FANCD2 foci
formation under these conditions demonstrated significant
inhibition at higher dosage (data not shown), consistently
with the initial screen. IR-induced monoubiquitination of
FANCD2 was in most cases moderately inhibited or
unaffected, with the exception of CA-074-Me, which
strongly inhibited it (Additional file 3: Figure S5). IR-
induced foci formation of BRCA1 was also mildly affected
or unaffected by the compounds (Figure 3 and Additional
file 6: Figure S4). By using higher concentrations for a
shorter time (8 hours drug exposure), we observed that
most drugs significantly inhibited IR-induced FANCD2,
RAD51 and BRCA1 foci formation, as well as IR-induced
FANCD2 monoubiquitination, in the absence of significant
variations of cell cycle distribution (data not shown). In
addition, most of the drugs significantly inhibited
cisplatin-induced FANCD2 foci formation in 24 hours co-
Table 1 List of the validated small molecule inhibitors of the FA pathway
Chemicals Primary known functions IC50 (μM)
Lactacystin Proteasome inhibitor 1.7
MG132 Proteasome and calpain inhibitor 0.8
ALLN Proteasome, calpain, cathepsin L inhibitor 9.2
5929407 Proteasome inhibitor (this study) 6.5
Curcumin Proteasome, protein kinase C (PKC), EGF-receptor tyrosine kinase, IkappaB kinase and mTOR inhibitor 18.6
H-9 PKA, PKC, PKG inhibitor 34.2
Gö6976 PKC, CHK1 inhibitor > 50
SB218078 CHK1, Cdc2, PKC inhibitor 1.4
UCN-01 PKC, CHK1, CDK, AKT inhibitor 0.14
Alsterpaullone CDK, GSK3 inhibitor 1.6
Roscovitine CDK, ERK1,2 inhibitor 27.5
Geldanamycin HSP90 inhibitor 0.15
17-AAG HSP90 inhibitor 0.6
CA-074-Me CathepsinB inhibitor 16.7
Chloroquine Lysosome permeabilisation, inhibition of drug efflux pumps (ATP-binding cassette transporters) 67.5
Wortmannin Casein kinase II, phosphatidylinositol 3-kinase (PI 3-kinase), polo-like kinase 1 (PLK1) inhibitor 84.4
DRB Casein kinase II, RNA pol II inhibitor 11
HNMPA-(AM)3 Insulin receptor tyrosine kinase inhibitor 4.7
Puromycin Protein synthesis inhibitor 5.2
TPEN Heavy metal chelator 5
5656325 Unknown 0.83
5315179 Unknown 5.9
7012246 Unknown 7
5195243 Unknown 2.2
5373662 Unknown 1.3
The identified chemicals are presented with their major known functions and the dose required to inhibit 50% of IR-induced EGFP-FANCD2 foci formation (IC50) in
PD20-EGFP-FANCD2 cells. Chemical structures of 5195243 (2-nitro-9,10-phenanthrenedione 10-oxime), 5373662 (2-(2-pyrinylmethylene)quinuclidin-3-one), 5656325
(1-(2-methoxy-1-naphtyl)-3-(3-pyridinyl)-2-propen-1-one), 5929407 (5-[4-(dietylamino)benzylidene]-3-{[(3-methylphenyl)amino]methyl}-2-thioxo-1,3-thiazolidin-4-
one), 5315179 (1-(2,4-dimethoxyphenyl)-3-(3-pyridinyl)-2-propen-1-one) and 7012246 (1-(5-bromo-2-hydroxyphenyl)-3-(3-pyridinyl)-2-propen-1-one)) are shown in
Additional file 2: Figure S1.
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results demonstrate that most FA pathway inhibitors
inhibit HR processes (RAD51 foci formation and HR
repair) in addition to FANCD2 foci formation, indicating
that the identified chemicals target multiple steps of the
DNA damage response pathway and are not specific for
FA pathway inhibition. The lack of inhibition of FANCD2
monoubiquitination suggests that the FA pathway inhibi-
tors may inhibit processes involved in the recruitment of
proteins at sites of damage, rather than damage signaling
upstream of FANCD2 monoubiquitination.
Identification of the compounds that synergize with
cisplatin in ovarian cancer cells
Since the integrity of the FA pathway is critical for cellular
resistance to ICL-inducing agents such as cisplatin, FA
pathway inhibitors may sensitize tumor cells to cisplatin in
an FA pathway-dependent manner. To test this hypothesis,
we performed isobologram analyses on the ovarian cancer
cell line 2008 [25], which is deficient in the FA pathway
due to hypermethylation of the FANCF promoter, and on
its isogenic, complemented FA pathway-proficient coun-
terpart 2008+FANCF cell line [11].
Figure 2 Identification of compound 5929407 as a proteasome inhibitor. (A) In vivo proteasome activity assay. Flow cytometry diagrams
showing proteasome inhibition-dependent expression of GFP in GFPu-1 cells treated with the indicated drugs (gray area), compared with non-
treated cells (white area). In the first panel, three independent non-treated samples are plotted to show variability. (B) Compounds with
proteasome inhibitor activity preferentially inhibit proteasome chymotrypsin- and caspase-like activities. Proteasome activities were monitored
using fluorogenic probes processed by cellular extracts obtained from HeLa cells exposed to the various proteasome inhibitors (n=3,
mean±SEM).
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the dose producing a 50% reduction of cell survival (LD50,
lethal dose 50%) was determined (Additional file 8:
Table S2). As previously reported [11], 2008 cells were
significantly more sensitive to cisplatin than 2008+FANCF
cells. 2008 and 2008+FANCF cells were equally sensitive
to all FA pathway inhibitors, except for puromycin and
geldanamycin. Higher tolerance of 2008+FANCF cells to
puromycin was likely due to the use of puromycin selec-
tion to generate the complemented cell line, and therefore,
puromycin was omitted from further analysis. The reason
for the differential sensitivity of 2008 and 2008+FANCF
cells toward geldanamycin remains unknown.
Next, isobolograms at the LD50 level were generated
following the method previously described [26]. Survival
assays were performed using the combination of 10
cisplatin concentrations with 6 concentrations of each FA
pathway inhibitor. LD50/LD500 unit (drug concentration
necessary to induce 50% death when combined with
cisplatin divided by the drug’sL D 5 0i nt h ea b s e n c eo f
cisplatin) values of each FA pathway inhibitor were plotted
against corresponding LD50/LD500 unit values of cisplatin.
The distribution of points along the line connecting values
of 1 corresponds to an additive effect of the two drugs while
scattering below or above represents synergism and
antagonism, respectively. In addition, combination index
(CI) values were calculated according to Chou and Tallay’s
method [26]; CI≤0.90 indicates synergism.
Analyses performed at 50% killing revealed that 11 FA
pathway inhibitors exhibited synergism with cisplatin in
2008 and/or 2008+FANCF cells (Figure 4, Additional file
9: Figure S7, summarized in Table 2). Bortezomib, 17-
AAG, CA-074-Me, and compounds 7012246 and 5373662
synergized with cisplatin in FA pathway-proficient
2008+FANCF cells, but not in their isogenic FA pathway-
deficient counterpart 2008, consistent with their FA
pathway inhibition activity. Geldanamycin, three CHK1
inhibitors (Gö6976, UCN-01, SB218078) and chloroquine
synergized with cisplatin in both 2008 and 2008+FANCF
cells. Geldanamycin, UCN-01 and SB218078 exhibited a
significantly stronger synergism in 2008+FANCF cells
than in 2008 cells (p≤0.01, unpaired t test), again consis-
tent with their FA pathway inhibition activity. Finally,
lactacystin weakly synergized with cisplatin in 2008 cells
only. The other compounds had either additive or
antagonistic effect with cisplatin.
Analyses performed at 70% killing (Additional file 10:
Table S3) showed that bortezomib, 17-AAG, and CA-074-
Me, in addition to geldanamycin, Gö6976, and UCN-01,
synergized with cisplatin in both 2008 and 2008+FANCF
Figure 3 Effects of 26 chemicals that inhibit the FA pathway on HR efficiency, IR-induced foci formation of FANCD2, RAD51 and BRCA1,
and IR-induced FANCD2 monoubiquitination. (See Additional file 4: Figures S2, Additional file 6: Figure S4, and Additional file 3: Figure S5 for
details) Color-coded representation of HR efficiency in DR-GFP assay, the proportion of cells with IR-induced foci of the indicated proteins, and the
proportion of FANCD2 monoubiquitinated form on Western blot (8 hours after 10 Gy), compared to untreated controls. U2OS-DR-GFP cells were
used for all the experiments. An asterisk (*) indicates significant decrease compared to controls (p ≤0.05, paired t test, n=3 to 7) in DR-GFP and
foci formation experiments. N.D. = not determined.
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the LD50 level obtained in at least 3 independent experiments performed with FA pathway-deficient ovarian cancer cells (2008) and their FA
pathway-proficient counterpart (2008+FANCF) are presented (except of lactacystin, for which the result of only one experiment is shown,
because of the high concentration required to achieve 50% killing). Average combination index (CI) is indicated in the upper right corner of each
isobologram: a CI≤0.90 indicates synergism. Results are summarized in Table 2.
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5315179 and 5373662 synergized with cisplatin in
2008+FANCF only.
Taken together, about half of the FA pathway inhibitors
sensitized ovarian cancer cells to cisplatin (11 of 25 at 50%
killing (Table 2) and 12 of 25 at 70% killing (Additional
file 10: Table S3)). Most of them exhibit a significantly
stronger synergism with cisplatin in FA pathway-proficient
2008+FANCF cells than in 2008 cells (CI significantly
lower for 2008+FANCF than 2008 (p≤0.05) for 8 of 11
drugs at 50% killing, for 9 of 12 drugs at 70% killing),
indicating that their effects are, at least partially, mediated
through inhibition of the FA pathway.
We also examined whether the compounds that most
significantly synergized with cisplatin would sensitize cells
to IR (Additional file 11: Figure S8 and Additional file 12:
Table S4). Geldanamycin and SB218078 synergized with
IR in both 2008 and 2008+FANCF cells, Gö6976 in 2008,
and compound 5373662 in 2008+FANCF cells. Other
compounds showed additive effects with IR.
Discussion
Here we identified 26 chemicals that inhibit the formation
of IR- and cisplatin-induced FANCD2 foci. Many demon-
strated a stronger inhibition of FANCD2 foci formation
than FANCD2 mono-ubiquitination, suggesting that at
Table 2 Drug interactions at 50% killing between cisplatin and the chemicals that inhibit the FA pathway in FA
pathway-deficient/proficient ovarian cancer cells
Interaction with cisplatin
2008 2008+FANCF
Chemicals FA-deficient FA-proficient
CI Interpretation CI Interpretation
Bortezomib 1.00±0.05 Additive 0.88±0.02 Moderate synergism
Lactacystin 0.90±0.05 Slight synergism 1.02±0.05 Additive
MG132 1.13±0.04 Slight antagonism 1.13±0.05 Slight antagonism
ALLN 1.17±0.04 Slight antagonism 1.06±0.09 Additive
5929407 1.10±0.04 Additive 1.00±0.04 Additive
Curcumin 0.98±0.02 Additive 1.06±0.02 Additive
H-9 1.08±0.04 Additive 0.98±0.04 Additive
Gö6976 0.63±0.04 Synergism 0.68±0.03 Synergism
SB218078 0.90±0.05 Slight synergism 0.77±0.03 Moderate synergism
UCN-01 0.83±0.03 Moderate synergism 0.66±0.04 Synergism
Alsterpaullone 1.05±0.03 Additive 1.15±0.03 Slight antagonism
Roscovitine 0.98±0.03 Additive 0.98±0.03 Additive
Geldanamycin 0.83±0.04 Moderate synergism 0.38±0.05 Synergism
17-AAG 1.06±0.10 Additive 0.87±0.04 Slight synergism
CA-074-Me 0.91±0.03 Additive 0.78±0.02 Moderate synergism
Chloroquine 0.88±0.05 Slight synergism 0.72±0.05 Moderate synergism
Wortmannin 1.08±0.05 Additive 1.12±0.05 Slight antagonism
DRB 1.08±0.04 Additive 0.97±0.05 Additive
HNMPA-(AM)3 0.96±0.02 Additive 0.91±0.03 Additive
Puromycin 1.08±0.03 Additive 0.88±0.04 Slight synergism
TPEN 1.16±0.08 Slight antagonism 1.13±0.04 Slight antagonism
5656325 0.99±0.03 Additive 1.05±0.05 Slight antagonism
5315179 1.14±0.09 Slight antagonism 0.94±0.04 Additive
7012246 1.18±0.05 Slight antagonism 0.87±0.04 Slight synergism
5195243 1.22±0.04 Moderate antagonism 1.02±0.02 Additive
5373662 1.08±0.04 Additive 0.90±0.04 Slight synergism
Combination index (CI) at 50% killing values (mean±SEM) calculated from isobologram at the LD50 level analyses of combination of cisplatin with each FA
pathway inhibitor, performed in FA-deficient (2008) and FA-proficient (2008+FANCF) ovarian cancer cell lines. See Figure 4 and Additional file 9: Figure S7 for
details. Interpretation of combination index values: 0.10<CI≤0.30, strong synergism; 0.30<CI≤0.70, synergism; 0.70<CI≤0.85, moderate synergism;
0.85<CI≤0.90, slight synergism; 0.90<CI≤1.10, additivity; 1.10<CI≤1.20, slight antagonism; 1.20<CI≤1.45, moderate antagonism [26]. Synergism is highlighted
in bold letters.
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ment at site of DNA damage more than with FANCD2
mono-ubiquination. However, the cathepsinB inhibitor
CA-074-Me demonstrated a stronger inhibition of
FANCD2 mono-ubiquitination than foci formation, sug-
gesting the intriguing possibility that recruitment of
FANCD2 at sites of DNA damages may be supported
with reduced levels of mono-ubiquitinated FANCD2.
Additionally, most chemicals also inhibited IR-induced
RAD51 foci formation and DNA double-strand break
repair by HR, but generally not BRCA1 foci formation,
indicating that they inhibit multiple discrete steps of the
DNA damage response and are not specific inhibitors of
the Fanconi anemia pathway.
Many of the identified chemicals appeared to cluster
around common targets, such as the proteasome, PKC,
CHK1, CDK, HSP90, cathepsin B and lysosome function,
or casein kinase II (Table 1). Some of these targets have
already been implicated in the FA pathway and HR. For
instance, proteasome function is required for activation of
the FA pathway and HR [18,27]. Consistent with this,
among the new FA pathway inhibitors, we identified
a novel and uncharacterized proteasome inhibitor
(5929407). ATR and its downstream kinase, CHK1, which
can be directly or indirectly inhibited by UCN-01, Gö6976,
SB218078, alsterpaullone, roscovitine and wortmannin, are
involved in FA pathway activation [28–31]. CHK1 inhibi-
tion also inhibits RAD51 binding to DNA [32]. HSP90 is
also implicated in the FA pathway and HR, since FANCA,
BRCA2, CHK1 and CDKs are clients of HSP90 [33–35].
CDK inhibition leads to perturbation of cell cycle,
proliferation and checkpoints, and compromises CHK1,
BRCA2 and RAD51 functions [36,37], which can lead to
impaired FA pathway and HR. A possible role for PKC,
cathepsin B, lysosome and casein kinase II in the
regulation of the FA pathway and HR has not been
reported yet, and is worth testing in the future. Whether
these chemicals directly target some components of the
FA pathway remains to be determined. Further studies
of the pathways affected by these inhibitors may shed
light on new regulatory mechanisms of the FA pathway
and HR.
A total of 14 out of the 26 chemicals that inhibit the FA
pathway sensitized ovarian cancer cells to cisplatin (Table 2
and Additional file 10: Table S3). The majority showed a
stronger synergism with cisplatin in FA-proficient than in
FA-deficient cells, suggesting that FA pathway inhibitory
activity of these compounds contributes to the cisplatin
sensitization. The chemicals that synergized with cisplatin
in both FA pathway-deficient and -proficient cells probably
did so through mechanisms independent of the FA path-
way, such as inhibition of RAD51 recruitment and HR, or
other mechanisms. The inhibition of the FA pathway and
these other mechanisms may independently or
synergistically participate in the increased sensitization to
cisplatin observed using these chemicals. Most synergistic
interactions between FA pathway inhibitors and cisplatin
were stronger at higher killing levels, suggesting that these
combinations are relevant for cancer therapy.
Although the role of the FA pathway in cellular resistance
to ICL-inducing agents, such as cisplatin, has been
established, some FA pathway inhibitors did not synergize
with cisplatin. Their activity on targets other than the FA
pathway may prevent chemosensitization. Alternatively,
cisplatin treatment may alleviate their toxicity. It is also
possible that the effects of combining cisplatin and the
inhibitors vary in cell type- and context-specific manners.
Whether the inhibitors synergize with cisplatin in different
types of tumor cells remains to be systematically
determined.
CHK1 inhibitors have been used in preclinical and
clinical trials to treat p53-deficient and, more recently,
p53-proficient cancers [38–41]. A CHK1 inhibitor,
Gö6976, has been suggested to sensitize FA-deficient cells
to cisplatin [42]. Our results showed that CHK1 inhibitors
sensitized p53 wild-type, FA-proficient and -deficient
ovarian cancer cells to cisplatin. SB218078 and UCN-01
showed a significantly stronger synergism with cisplatin in
the FA-proficient cell line than in the FA-deficient cell line
(p=0.01 and 2x10
-5 respectively at 50% killing), while no
difference between the two cell lines was detected with
Gö6976.
HSP90 inhibitors have also been shown to sensitize
tumor cells to DNA damaging agents including cisplatin
[43,44]. In the current study, geldanamycin and, to a lesser
extent, 17-AAG sensitized cells to cisplatin. Downregula-
tion of multiple HSP90 clients involved in the FA pathway
and HR (FANCA, BRCA2, CHK1, CDK) may result in the
observed sensitization to cisplatin. However, a recent
phase I clinical trial in patients with refractory tumors
for combination therapy using cisplatin and 17-AAG
demonstrated that the combination had anti-tumor
activity, but exhibited significant toxicity, preventing any
phase II development [45].
Chemicals that inhibit proteasome (bortezomib and,
more marginally, lactacystin and ALLN) or lysosome
function (CA-074-Me and chloroquine) sensitized ovarian
cancer cells to cisplatin. Bortezomib and CA-074-Me
showed a stronger synergism with cisplatin in FA-
proficient than in FA-deficient cells, consistent with
inhibition of the FA pathway by these drugs. The
mechanism of FA pathway inhibition by these chemicals
remains unknown. Proteasomes and lysosomes are protein
degradation systems that can contribute to cellular
tolerance to various proteotoxic stressors, and can confer
resistance to chemo-, radio- and immunotherapy [46]. It is
possible that perturbed protein degradation interferes with
the FA pathway. Alternatively, the FA pathway may
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Chloroquine has already demonstrated potential to
enhance the effect of radiation therapy and chemotherapy
with vincristine, Akt inhibitors, and histone deacetylase
inhibitors through its inhibition of lysosome function and
autophagy [47]. Our study suggests that chloroquine can
potentiate the cytotoxic effects of cisplatin. Combination
of chloroquine and cisplatin is undergoing a clinical
trial for the treatment of small cell lung cancer (http://
clinicaltrials.gov/). This work suggests that combination of
chloroquine and cisplatin may also have therapeutic
advantages in cisplatin-resistant ovarian cancer treatment.
Combinations of bortezomib and platinum compounds
(cisplatin or carboplatin) are also undergoing clinical trials
for the treatment of ovarian and other cancers (http://
clinicaltrials.gov/).
Our study identified four Chembridge compounds
without known bioactivities as FA pathway inhibitors that
can sensitize ovarian cancer cells to cisplatin. Three of
these compounds have a related structure (5656325,
5315179 and 7012246), and show some synergism
with cisplatin at higher killing level (Additional file 10:
Table S3). Interestingly, compound 5373662 showed syn-
ergism with cisplatin and with IR in FA-proficient cells
only. Further analyses of its mechanism(s) of action, as
well as analyses of related compounds, are warranted.
The ATM kinase, involved in DNA damage response,
has been identified as a synthetic lethal gene in FA-
deficient cells [48]. Whether the FA pathway inhibitors
specifically kill ATM-deficient tumor cells is another
important question.
In summary, this study underscores the potential clinical
benefit of combination therapy using cisplatin and
inhibitors of CHK1, HSP90, and protein degradation
machineries (proteasome and lysosome), during treatment
of cisplatin-resistant tumors. In addition, we identified
four new small molecules that synergize with cisplatin
(and, in one case, IR). Our results provide a rationale for
further development of new generations of analog drugs
with improved specificity and decreased toxicity, as well as
pre-clinical testing in appropriate animal models. Further
evaluation of these combinations in cisplatin-resistant
tumors may lead to the development of efficient cancer
treatments.
Materials and methods
Cell lines and culture conditions
HeLa, U2OS, TOV-21 G and GFPu-1 cells were purchased
from the American Type Culture Collections (Manassas,
VA). 2008 and FANCF-corrected 2008+FANCF ovarian
cancer cells, TOV-21 G and FANCF-corrected TOV-
21 G+FANCF ovarian cancer cells were described
previously [11]. FANCD2-deficient fibroblast line (PD20),
PD20 corrected with wild-type FANCD2 (PD20-FANCD2)
and enhanced green fluorescent protein (EGFP)-FANCD2
(PD20-EGFP-FANCD2 clone 7) were described previously
[13]. U2OS-DR-GFP cells were a gift from Drs. Maria
Jasin and Koji Nakanishi [49]. Cell lines were grown in
DMEM supplemented with 10% fetal calf serum. Gamma
irradiation was delivered using a JL Shepherd Mark I
Cesium Irradiator (JL Shepherd & Associates).
The present research has been approved by the
Institutional Review Board (IRB) Committee at the Fred
Hutchinson Cancer Research Center (IRB Protocol file
number 6023).
Chemicals
The chemical libraries (ICCB bioactives (489 compounds),
Commercial Diversity Set 1 (5,056 compounds),
Chembridge DiverSet Library (10,000 compounds) and
NINDS II library (1,040 compounds) were used to identify
inhibitors of the FA pathway. For subsequent studies,
chemicals were purchased from Biomol (lactacystin,
penitrem A, splitomicin, (±)-13-HODE), EMD biochemicals
(actinomycin D, AG213, AG370, ALLN, alsterpaullone, α-
amanitin, BAPTA-AM, bumetanide, CA-074-Me, curcumin,
DRB, geldanamycin, Gö6976, HNMPA-(AM)3,H - 9 ,K -
252c, MG132, nifedipine, propidium iodide, puromycin,
roscovitine, SB218078, spermine NONOate, TPEN, trichos-
tatin A, wortmannin), Cayman Chemical (leukotriene B3),
Chembridge Corporation (5195243, 5315179, 5373662,
5656325, 5929407, 7012246), Fisher (chloroquine), Millen-
ium Pharmaceutical (bortezomib), MP (3-methyladenine),
Sigma (cisplatin, UCN-01), Tocris (ochratoxin A), VWR
(17-AAG).
Screen for small molecules that inhibit the FA pathway
The PD20-EGFP-FANCD2 clone 7 was used in the screen
[13]. The cell-based screening of ICCB bioactives and
Commercial Diversity Set 1 was done at the Institute for
Chemistry and Cell Biology (Boston, MA) and a partial
result was previously reported [13]. The cell-based
screening of Chembridge DiverSet Library and NINDS II
library was done at Fred Hutchinson Cancer Research
Center. For this screening, duplicate 96-well plates were
seeded with PD20-EGFP-FANCD2 clone 7 cells (10,000
cells per well). Chemical compounds from the library were
added, five compounds per well, at a single concentration
of 7.5 μmol/L. After a 12-hour incubation, cells were
irradiated (15 Gy) and fixed for EGFP microscopy 12 hours
later. Photomicrographs were obtained for each well and
wells with significant (50%) reduction in percentage of
EGFP-FANCD2 foci positive cells were identified by visual
inspection. The five compounds of each well identified
with reduced EGFP-FANCD2 foci were then individually
tested.
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described previously [18]. Antibodies against BRCA1
(D-9, Santa Cruz, 1/100), γH2AX (JBW301, Upstate, 1/
1000), FANCD2 (NB 100–182, Novus Biologicals, 1/
1000) and RAD51 (PC130, Calbiochem, 1/1000 or H-92,
Santa Cruz, 1/200) were used. Species-specific fluores-
cein isothiocyanate (FITC)- or Cy3-conjugated second-
ary antibodies (Jackson Immunoresearch (West Grove,
PA)) diluted in blocking buffer (1/2000) were incubated
for 1 hour at room temperature. Images were acquired
using a microscope (TE2000, Nikon, Tokyo, Japan)
equipped with a 40x immersion objective (1.3NA) and a
CCD camera (CoolSnap ES, Photometrics, Tucson, AZ)
controlled by MetaVue (Universal Imaging, Downing-
ton, PA) and analyzed using MetaVue or ImageJ soft-
wares. At least 100 cells per experimental point were
scored for presence of foci, and each experiment
repeated at least 3 times independently.
Flow cytometric analyses
Exponentially growing cells were plated in drug-free
medium 48 hours before experiment. For proteasome
activity assay [19], GFPu-1 cells were exposed to drugs at
the indicated concentration for 24 hours, then analyzed
for green fluorescent protein (GFP) expression. For cell
cycle analyses, cells were exposed to drugs at the indicated
concentration for 24 hours, and exposed to IR 8 hours
before being pulse-labeled with 30 μM5 - B r o m o - 2 ’-deoxy-
Uridine (BrdU (Sigma)) for 15 minutes, washed and fixed
with 70% ice-cold ethanol. Cells were then stained for
DNA content (propidium iodide, PI) and BrdU incorpo-
ration with anti-BrdU rat monoclonal antibody (MAS250,
Harlan Sera Lab, UK) followed by FITC-conjugated
goat anti-rat antibody (Jackson Immunoresearch). For
HR assays, cells were transfected with pCBASce (a
hemagglutinin (HA)-tagged I-Sce1 expression vector) [50]
or the empty pCAGGS vector using TransIT transfection
reagent (Mirus) following manufacturer recommenda-
tions. 24 hours after transfection, cells were treated with
the indicated drugs at the indicated concentration for 24
hours. Cells were then fixed and stained for HA expression
with mouse anti-HA antibody (HA.11, Convance, USA,
1/1000) followed by APC-conjugated donkey anti-mouse
antibody (Jackson Immunoreserach). To specifically deter-
mine the proportion of HR events in I-Sce1 expressing
cells, the percentage of GFP-positive cells among the HA-
positive cell population was quantified. Flow cytometric
analyses were performed on a Becton Dickinson FACScan.
Fluorescence data were plotted using FlowJo (Tree Star,
Inc., Ashland, OR). At least three independent experi-
ments were carried out for each condition.
Proteasome activity fluorogenic assays were per-
formed as in [51]. Briefly, HeLa cells were treated with the
indicated FA pathway inhibitors for 6 hours, scrapped,
washed in cold PBS, and lysed by 30 minutes incubation
in 5 mM EDTA on ice. Cellular extracts were cleared by
centrifugation (10,000 rpm, 5 min, 4°C) and quantified.
Fluorogenic peptides specific for the chymotrypsin-like,
trypsin-like and caspase-like activities of the proteasome
(Suc-LLVY-AMC, Boc-LLR-AMC, Z-LLQ-AMC respec-
tively (Bachem)) were incubated with 5 ug HeLa extracts
in specific substrate buffers [51]. Fluorescence emitted by
proteasome cleavage of the peptides was monitored every
200 seconds for 1 hour using a fluorometer (Hitachi
F-4500 fluorometer) with 380 nm and 440 nm excitation
and emission filters, respectively, and maximum linear
slopes were measured. Emission of serial dilutions of
AMC in extracts was used for fluorometer calibration.
Proteasome activity was calculated as concentration of
AMC (pM) produced per second per mg of protein. Three
independent experiments were performed.
Drug interaction analysis
2008 and 2008+FANCF cells were plated in 96-well plates
at a density of 2000 cells/well. 24 h after plating, cisplatin
and FA pathway inhibitors were added concomitantly, or
FA pathway inhibitors were added and the cells immediately
exposed to IR. Cytotoxicity was measured using the stand-
ard crystal violet assay 6 days after drug addition: cells were
washed twice with PBS, fixed for 5 minutes at room
temperature in 10% (v/v) methanol and 10% (v/v) acetic
acid. Adherent colonies were stained for 2 to 10 minutes
with 1% (w/v) crystal violet (Sigma) in methanol, rinsed in
distilled water, and dried before the adsorbed dye was re-
solubilized with methanol containing 0.1% (w/v) SDS by
gentle agitation for 1 to 4 hours at room temperature. Dye
concentration was quantified using ELx800 Universal
Microplate Reader (Bio-Tek Instruments, Inc.) at 595 nm.
For quantitation, readings of absorbance at 595 nm were
normalized to those obtained from untreated cells, assumed
to yield 100% cell survival, and empty wells, considered to
be 0% cell survival. Cytotoxicity results were analyzed as
described [52]. Briefly, after each experiment, survival
curves were generated, for cisplatin and each FA pathway
inhibitor alone and for the drug combinations. The LD50s
for each drug in combination were determined, and LD50/
LD500 units were derived as ratio of LD50 for cisplatin or
IR and the FA pathway inhibitor relative to LD50 of each
drug alone (this value was designated as 1) for each cell line.
Isobolograms were generated at LD50 levels. Each plot pre-
sents values generated in at least three independent experi-
ments. In addition, combination index (CI) values were
calculated by the use of the Chou and Talladay method
[26]. An identical analysis was performed at the 70% killing
level.
Western blot analysis was done as described [18].
Anti- FANCD2 (NB 100–182, Novus Biologicals, 1/20,000
dilution) and HRP-conjugated ECL anti-rabbit IgG
Jacquemont et al. Molecular Cancer 2012, 11:26 Page 12 of 15
http://www.molecular-cancer.com/content/11/1/26(Amersham, 1/5000) were used. Films were digitalized
using a standard scanner and images processed using
ImageJ.
Additional files
Additional file 1: Table S1. List of the chemicals scored as positives in
the primary screening. The 43 compounds scored as FA pathway
inhibitors in the primary screening are listed. The 15 compounds that wre
verified in the secondary screenings are indicated with “X”.
Additional file 2: Figure S1. Chemical structure of the Chembridge
library compounds that inhibit DNA damage-induced FANCD2 foci
formation. Compounds 5195243, 5373662, 5929407 and 5656325 were
identified by the compound library screening. Compounds 5315179 and
7012246 were later selected upon their 2D analogy with 5656325.
Additional file 3: Figure S5. Some FA pathway inhibitors inhibit IR-
induced FANCD2 monoubiquitination in U2OS-DR-GFP cells. U2OS-DR-
GFP cells were exposed to FA pathway inhibitors for 24 hours using the
concentrations used for the HR and foci formation assays, and irradiated
with 10Gy 8 hours before the end of the exposure to the drugs. Whole
cell lysates were subjected to FANCD2 western blotting. The ratio of
ubiquitinated versus non- ubiquitinated FANCD2 is indicated for each
condition. These results are summarized in Figure 3.
Additional file 4: Figure S2. Most FA pathway inhibitors inhibit HR. (A)
Schematic of the HR assay performed using FA pathway inhibitors. (B)
Flow cytometric analysis for HR efficiency using U2OS-DR-GFP cells and
HA-tagged I-Sce1. Cells fixed and stained with anti-HA and APC-linked
specific secondary antibodies were first gated in FCS/SSC scatter, then
HA-positive population was gated in an APC/GFP dot plot and analyzed
for GFP expression using a red/GFP dot plot. (C) The relative proportion
of live cells compared to non-treated control cells in the HR assay in
U2OS-DRGFP cells are shown (mean ± SEM (n=3 to 7)). Percentage of live
cells was 95.0±1.2% in non-treated condition. (D) The relative proportion
of cells expressing HA-tagged ISce1 compared to non-treated control
cells in the HR assay in U2OS-DRGFP cells are shown (mean ± SEM (n=3
to 7)). An asterix (*) indicates significant decrease in proportion of HA-
positive cells upon exposure to the indicated drug (p≤0.05, t test).
Percentage of HA-positive cells was 39.2±2.5% in non-treated condition.
(E) The relative proportion of GFP-positive cells in the HA-positive
population, compared to non-treated control cells, is shown (mean ±
SEM (n=3 to 7)). An asterix (*) indicates significant decrease in the
proportion of GFP-positive/HA-positive cells upon exposure to the
indicated drug (p≤0.05, t test). Percentage of GFP-positive/HA-positive
cells was 9.5±0.9% in non-treated condition. These results are
summarized in Figure 3. (F) Examples of flow cytometric profiles obtained
with U2OS-DR-GFP cells untreated and treated with geldanamycin
(0.1μM) for 24 hours.
Additional file 5: Figure S3. Most FA pathway inhibitors do not
significantly affect the proportion of cells in S+G2phases of the cell cycle.
Cell cycle distribution quantified using BrdU/PI staining of U2OS-DR-GFP
cells treated for 24 hours with the indicated drugs (A), or treated for 24
hours with the indicated drugs and irradiated with 10Gy 8 hours before
the end of treatment (B) (n=3 to 4). An asterix (*) indicates significant
decrease in proportion of S+G2 cells upon exposure to the indicated
drug (p≤0.05, t test). Examples of flow cytometric profiles obtained with
non-treated and FA pathway inhibitor-treated cells are shown.
Additional file 6: Figure S4. Most FA pathway inhibitors significantly
inhibit IR-induced foci formation of FANCD2 and RAD51 in U2OS-DR-GFP
cells, while some of them significantly inhibit IR-induced foci formation of
BRCA1. Relative proportion of U2OS-DR-GFP cells with more than 5
FANCD2 (A), RAD51 (B), or BRCA1 (C) foci 8 hours after 10Gy irradiation,
compared to controls (mean ± SEM (n=3 to 7)). An asterisk (*) indicates
significant decrease in the proportion of foci-positive cells compared to
controls (p ≤0.05, t test). In non-treated conditions, the percentage of
FANCD2-positive cells was 76.4 ± 2.4%, the percentage of RAD51-positive
cells was 57.8 ± 2.5%, and the percentage of BRCA1-positive cells was
85.3 ± 1.7%. Examples of immunofluorescence staining are also shown.
Scale bar =20uM. These results are summarized in Figure 3.
Additional file 7: Figure S6. Most FA pathway inhibitors significantly
inhibit cisplatin-induced foci formation of FANCD2 in U2OS-DR-GFP cells.
Relative proportion of U2OS-DR-GFP cells with more than 10 foci after
24hour incubation with 5μM cisplatin and the indicated drug, compared
to controls (mean ± SEM (n=3)). An asterisk (*) indicates significant
decrease in the proportion of foci-positive cells compared to controls (p
≤0.05, t test). In non-treated conditions, the percentage of FANCD2-
positive cells was 83.13 ± 8.3%. Examples of immunofluorescence staining
are also shown. Scale bar = 20μm. N.D. = not determined.
Additional file 8: Table S2. 2008 and 2008+FANCF cells are equally
sensitive to most FA pathway inhibitors. Lethal dose 50 (LD50) (mean ±
SEM (n=3 to 6)) of the FA pathway inhibitors in 2008 and 2008+FANCF
cells. An asterisk (*) indicates significant difference in sensitivity between
2008 and 2008+FANCF cells (p ≤0.05, paired t test). N.D. = not
determined. Only two experiments were performed using lactacystin,
because of the high concentration required to achieve 50% killing.
Additional file 9: Figure S7. Isobologram analyses at 50% killing of the
FA pathway inhibitors that did not sensitize 2008 or 2008+FANCF ovarian
cancer cells to cisplatin. Isobolograms at the LD50 level are presented,
showing the results obtained in at least 3 independent experiments.
Results are summarized in Table 2.
Additional file 10: Table S3. Drug interactions at 70% killing between
cisplatin and the FA pathway inhibitors in FA pathway-deficient and
-proficient ovarian cancer cells. Combination index (CI) at 70% killing
values (mean ± SEM) calculated from isobologram at the LD70 level
analyses of combination of cisplatin with all FA pathway inhibitor,
performed in an FA-deficient (2008) and an FA-proficient (2008+FANCF)
ovarian cancer cell lines. Synergism is indicated in bold text.
Additional file 11: Figure S8. Isobologram analyses for sensitization to
IR of the FA pathway inhibitors that most significantly sensitize 2008 and/
or 2008+FANCF ovarian cancer cells to cisplatin. Isobolograms at the
LD50 level are presented, showing the results obtained in at least 3
independent experiments. Average combination index (CI) is indicated in
the upper right corner of each isobologram: a CI≤0.90 indicates
synergism. Results are summarized in Additional file 12: Table S4.
Additional file 12: Table S4. Interactions at 50% killing between IR and
the FA pathway inhibitors in FA pathway-deficient and -proficient ovarian
cancer cells. Combination index (CI) at 50% killing values (mean ± SEM)
calculated from isobologram at the LD50 level analyses of combination of
IR with each FA pathway inhibitor, performed in FA-deficient (2008) and
FA-proficient (2008+FANCF) ovarian cancer cell lines (see Additional file
11: Figure S8). Synergism is indicated in bold text.
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